- Home
- TARS vs LNN Comparison
TARS vs LNN Comparison
Compare TARS & LNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- LNN
- Stock Information
- Founded
- TARS 2016
- LNN 1954
- Country
- TARS United States
- LNN United States
- Employees
- TARS N/A
- LNN N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- LNN Industrial Machinery/Components
- Sector
- TARS Health Care
- LNN Industrials
- Exchange
- TARS Nasdaq
- LNN Nasdaq
- Market Cap
- TARS 1.7B
- LNN 1.5B
- IPO Year
- TARS 2020
- LNN 1988
- Fundamental
- Price
- TARS $41.29
- LNN $143.68
- Analyst Decision
- TARS Strong Buy
- LNN Hold
- Analyst Count
- TARS 7
- LNN 1
- Target Price
- TARS $67.14
- LNN $136.00
- AVG Volume (30 Days)
- TARS 605.1K
- LNN 172.5K
- Earning Date
- TARS 08-07-2025
- LNN 06-26-2025
- Dividend Yield
- TARS N/A
- LNN 0.99%
- EPS Growth
- TARS N/A
- LNN 5.71
- EPS
- TARS N/A
- LNN 6.96
- Revenue
- TARS $233,674,000.00
- LNN $677,807,000.00
- Revenue This Year
- TARS $122.94
- LNN $11.97
- Revenue Next Year
- TARS $44.14
- LNN $1.57
- P/E Ratio
- TARS N/A
- LNN $20.91
- Revenue Growth
- TARS 449.03
- LNN 9.46
- 52 Week Low
- TARS $20.08
- LNN $109.27
- 52 Week High
- TARS $57.28
- LNN $150.96
- Technical
- Relative Strength Index (RSI)
- TARS 49.21
- LNN 57.37
- Support Level
- TARS $38.52
- LNN $140.82
- Resistance Level
- TARS $41.48
- LNN $149.16
- Average True Range (ATR)
- TARS 1.57
- LNN 4.68
- MACD
- TARS 0.19
- LNN 0.46
- Stochastic Oscillator
- TARS 79.63
- LNN 59.19
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About LNN Lindsay Corporation
Lindsay Corp provides various proprietary water management and road infrastructure products and services. It has operations categorized into two main reporting segments: Irrigation, and Infrastructure. The company generates maximum revenue from the Irrigation segment. Its Irrigation segment includes manufacturing and marketing center pivot, lateral move, and hose reel irrigation systems, as well as various technology solutions such as GPS positioning and guidance, variable rate irrigation, wireless irrigation management, M2M communication technology, and smartphone applications. Geographically, it derives a majority of its revenue from the United States.